February 23, 2012 – On May 12, 2012, in Santa Monica, CA, mesothelioma experts from around the world will gather for the 2nd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma. The discussions will continue those started at the 1st annual International Symposium where specialists reviewed the Mesothelioma And Radical Surgery (MARS) trial from the UK and unanimously concluded that patients with mesothelioma no longer should be subjected to lung-removing surgery (EPP). The goal of the annual Symposiums is to make lung-sparing approaches the standard of care for mesothelioma.
Dr. Robert Cameron, Director of the UCLA Mesothelioma Comprehensive Research Program and Chief of Thoracic Surgery at the West Los Angeles VA Medical Center, will again lead the Symposium. Dr. Cameron has nearly 20 years of experience with treating patients with Malignant Pleural Mesothelioma and, in particular, lung-sparing therapies, including pleurectomy and decortication surgical procedures and a number of adjuvant therapies. His goal is to treat Malignant Pleural Mesothelioma like a chronic illness, instead of a fatal disease.
Although the Symposium is designed for physicians seeking continuing medical education (CME) credit, it is open to medical students and residents, nurses, mesothelioma victims and their families, students and other interested parties. The speakers will include faculty and experts from California, Houston, New York and South Africa with a wide range of medical and scientific expertise. Topics will include advances in lung-sparing surgical procedures and lung-sparing adjuvant therapies, as well as pain management, patient options for participation in mesothelioma research, and global trends for the prevention of asbestos exposure.